Hennell Medi Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.35 M
as on 23-10-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 194.12%
(FY 2023)
- Profit -700.00%
(FY 2023)
- Ebitda -195.81%
(FY 2023)
- Net Worth -0.04%
(FY 2023)
- Total Assets 1.90%
(FY 2023)
About Hennell Medi Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.35 M, as per Ministry of Corporate Affairs (MCA) records.
Chanda Narang, Archana Kumari, Parmod Dutt, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232DL2010PTC201052
- Company No.
201052
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Apr 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hennell Medi Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chanda Narang  | Director | 01-Apr-2010 | Current |
| Archana Kumari | Director | 25-Nov-2014 | Current |
| Parmod Dutt | Director | 16-Dec-2022 | Current |
| Yashpal Bhati | Director | 01-Apr-2010 | Current |
Financial Performance and Corporate Structure Insights of Hennell Medi Pharma.
Hennell Medi Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 194.12% increase. The company also saw a substantial fall in profitability, with a 700% decrease in profit. The company's net worth dipped by a decrease of 0.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hennell Medi Pharma?
In 2023, Hennell Medi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hennell Divine Collections Private LimitedActive 14 years 8 monthsParmod Dutt and Yashpal Bhati are mutual person
- Frazer And Haws International Private LimitedActive 25 years 7 days
Yashpal Bhati is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hennell Medi Pharma?
Unlock and access historical data on people associated with Hennell Medi Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hennell Medi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hennell Medi Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
